Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.61 |
| ▸ | HPD | P32754 | 2/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034920 | 0.81 | TGM2 (0.60) | TGM2 | |
| SCHEMBL6033953 | 0.80 | TGM2 (0.62) | TGM2 | |
| SCHEMBL6037629 | 0.79 | TGM2 (0.61) | TGM2 | |
| SCHEMBL6034313 | 0.77 | TGM2 (0.64) | TGM2 | |
| SCHEMBL6037628 | 0.77 | TGM2 (0.64) | TGM2TP53 | |
| SCHEMBL6037626 | 0.77 | TGM2 (0.65) | TGM2TP53 | |
| SCHEMBL6034418 | 0.76 | TGM2 (1.00) | TGM2 | |
| SCHEMBL6034031 | 0.76 | TGM2 (0.75) | TGM2THRB | |
| SCHEMBL6034265 | 0.70 | ALDH1A1 (0.52) | TGM2 | |
| SCHEMBL6037624 | 0.70 | TGM2 (0.61) | TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183759-A1 | Tissue transglutaminase inhibitors | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2006-08-17 | — | — | US | disclosed |
| WO-2006060702-A1 | SUBSTITUED 3,4-DIHYDROTHIENO [2,3-D] PYRMIDINES AS TISSUE TRANSGLUTAMINASE INHIBITORS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183759-A1 | Tissue transglutaminase inhibitors | TGM2, HNMT, TPMT | TGM2 1/4885HPD 657/4885MPI 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.